Tag: investor

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.

CHICAGO, July 25, 2025 (GLOBE NEWSWIRE) -- Amplify ETFs today announced that the net asset value (NAV) of the Breakwave Tanker Shipping ETF (BWET) was increased by $0.1465 per share on July 23, 2025. This adjustment is a result of a security pricing error in calculating the Fund’s NAV.

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

ATLANTA, July 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

WUXI, China, July 25, 2025 (GLOBE NEWSWIRE) -- LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), a developer and manufacturer in electric mobility and intelligent systems, today issued a statement regarding recent trading activity in its common stock.

DUBLIN, July 25, 2025 (GLOBE NEWSWIRE) -- Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), a provider of integrated energy solutions, today announced that, in July 2025, its majority-owned operating subsidiary, Al Shola Al Modea Gas Distribution LLC (“Al Shola Gas”), confirmed a number of new projects for the installation and maintenance of liquefied petroleum gas (“LPG”) systems and the supply of bulk LPG across multiple large-scale residential and commercial developments in Dubai, United Arab Emirates.